Security
NovaBridge Biosciences American Depositary Shares · NBP
NBPNASDAQotherCurrentCIK 1778016Updated Oct 14, 2026
Name history
I-Mab · through Oct 28, 2025
NBP price & chart
Loading TradingView…
NASDAQ:NBP on TradingView ↗About the company
NovaBridge Biosciences ("NovaBridge") (NASDAQ: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing and partnering strategy best suited to each program. NovaBridge's portfolio is led by givastomig, a Claudin 18.2 × 4-1BB bispecific antibody being developed for the potential treatment of gastrointestinal malignancies, and Visara, its majority-owned ophthalmology subsidiary. Through Visara, NovaBridge is building a diversified ophthalmology franchise designed to address unmet needs across diseases of the front and back of the eye.
In the news
NovaBridge Biosciences to Participate in September Investor Conferences ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 260,522,000Source | 212,680,000Source | 368,028,000Source | 590,625,000Source |
| Property, Plant and Equipment, NetUSD | 140,000Source | 201,000Source | 5,142,000Source | 8,821,000Source |
| GoodwillUSD | — | — | — | 23,571,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | 16,635,000Source | 17,237,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 210,632,000Source | 68,263,000Source | 301,616,000Source | 465,987,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentCNY | — | — | — | 0Source |
| Inventory, NetCNY | — | — | — | 0Source |
| Assets, CurrentUSD | 217,520,000Source | 176,693,000Source | 329,113,000Source | 525,789,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,678,000Source | 3,295,000Source | 7,325,000Source | 11,639,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,809,000Source | 3,597,000Source | 6,535,000Source | 9,152,000Source |
| Other Assets, NoncurrentUSD | 2,812,000Source | 1,365,000Source | 603,000Source | 1,582,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 29,581,000Source | 11,520,000Source | 126,031,000Source | 168,729,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 27,000Source | 19,000Source | 19,000Source | 19,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,332,308,000Source | -1,286,039,000Source | -1,172,952,000Source | -994,918,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 41,546,000Source | 33,384,000Source | 42,013,000Source | 30,997,000Source |
| Stockholders' Equity Attributable to ParentUSD | 230,941,000Source | 201,160,000Source | 241,997,000Source | 421,896,000Source |
| Additional Paid in Capital, Common StockUSD | 1,526,718,000Source | 1,460,021,000Source | 1,380,918,000Source | 1,388,879,000Source |
| Liabilities and EquityUSD | 260,522,000Source | 212,680,000Source | 368,028,000Source | 590,625,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 26,894,000Source | 8,454,000Source | 58,003,000Source | 109,923,000Source |
| Operating Lease, Liability, CurrentUSD | 891,000Source | 816,000Source | 3,083,000Source | 3,474,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,176,000Source | 3,066,000Source | 3,253,000Source | 4,650,000Source |
| Other Liabilities, NoncurrentUSD | 511,000Source | 0Source | 9,811,000Source | 2,459,000Source |
| Additional Financial Items | ||||
| Short-term InvestmentsUSD | 210,000Source | 105,135,000Source | 20,172,000Source | 34,134,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -88,340,000Source | — | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | 300,000Source | 3,400,000Source | 3,700,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,974,000Source | -1,949,000Source | 27,184,000Source | 51,782,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | -4,796,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | -3,949,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | -183,798,000Source | -159,892,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | 14,439,000Source | 66,459,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 7,000Source | 48,000Source | 1,599,000Source | 6,645,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | 1,066,000Source | 6,141,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 142,369,000Source | -242,404,000Source | -156,397,000Source | -30,863,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 210,632,000Source | 68,263,000Source | 309,914,000Source | 480,016,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 99,000Source | — |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 1,500,000Source | 27,862,000Source | 53,789,000Source |
| Amortization of Intangible AssetsUSD | — | — | 110,000Source | 113,000Source |
| Deconsolidation, Gain (Loss), AmountUSD | — | — | -1,113,000Source | — |
| DepreciationUSD | 68,000Source | 261,000Source | 3,373,000Source | 3,674,000Source |
| Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of TaxUSD | — | 34,364,000Source | — | — |
| Equity Method Investment, Other than Temporary ImpairmentCNY | — | — | 0Source | 0Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | -5,164,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -4,000Source | -5,573,000Source | -8,550,000Source | -25,429,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -16,000Source | 11,000Source | -69,000Source | -17,000Source |
| General and Administrative ExpenseUSD | 31,364,000Source | 29,656,000Source | 63,806,000Source | 118,275,000Source |
| GoodwillUSD | — | — | — | 23,571,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 22,898,000Source | 0Source |
| Impairment of Intangible Assets, Finite-livedCNY | — | — | 0Source | 0Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -46,269,000Source | -49,696,000Source | -196,988,000Source | -285,546,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -88,340,000Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 0Source | 27,466,000Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | -1,038,000Source | -11,270,000Source | -63,426,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | — | 101,000Source |
| Investment Income, InterestUSD | 7,611,000Source | 7,486,000Source | 7,289,000Source | 3,901,000Source |
| Net Income (Loss) Attributable to ParentUSD | -46,269,000Source | -22,230,000Source | -206,439,000Source | -363,526,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -42,071,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -206,439,000Source | -363,526,000Source |
| Operating ExpensesUSD | 94,269,000Source | 51,426,000Source | — | — |
| Other Nonoperating Income (Expense)USD | -1,682,000Source | -4,718,000Source | -5,368,000Source | -18,353,000Source |
| Payments to Acquire InvestmentsUSD | — | — | 124,731,000Source | 1,073,962,000Source |
| Proceeds from Stock Options ExercisedUSD | 200,000Source | — | 393,000Source | 6,474,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | 3,893,000Source | -32,124,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -94,269,000Source | -51,426,000Source | — | — |
| Other Nonoperating Income (Expense)USD | -1,682,000Source | -4,718,000Source | -5,368,000Source | -18,353,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -88,340,000Source | -49,696,000Source | -206,439,000Source | -363,425,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | — | 101,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -42,071,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -46,269,000Source | -22,230,000Source | -206,439,000Source | -363,526,000Source |
| Earnings Per Share, BasicUSD per share | -0.21Source | -0.12Source | -1.08Source | -1.92Source |
| Earnings Per Share, DilutedUSD per share | -0.21Source | -0.12Source | -1.08Source | -1.92Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 220,258,932Source | 186,728,372Source | 191,423,850Source | 189,787,292Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 220,258,932Source | 186,728,372Source | 191,423,850Source | 189,787,292Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | 110,000Source | 113,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -4,000Source | -5,573,000Source | -8,550,000Source | -25,429,000Source |
| General and Administrative ExpenseUSD | 31,364,000Source | 29,656,000Source | 63,806,000Source | 118,275,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 22,898,000Source | 0Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -46,269,000Source | -49,696,000Source | -196,988,000Source | -285,546,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -9,024,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -88,340,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -0.21Source | -0.27Source | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -0.21Source | -0.27Source | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 0Source | 27,466,000Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | -1,038,000Source | -11,270,000Source | -63,426,000Source |
| Interest ExpenseUSD | — | — | 102,000Source | 1,000Source |
| Investment Income, InterestUSD | 7,611,000Source | 7,486,000Source | 7,289,000Source | 3,901,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -206,439,000Source | -363,526,000Source |
| Operating ExpensesUSD | 94,269,000Source | 51,426,000Source | — | — |
| Other IncomeUSD | — | 1,300,000Source | 8,569,000Source | 2,821,000Source |
| Research and Development ExpenseUSD | 62,905,000Source | 21,770,000Source | 114,177,000Source | 131,198,000Source |
Filing attachments
nbp-ex99_1.htm · 6-K · 2026-10-13
Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis Visara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2 Visara plans to develop HT006.2.2 as VIS-102, its second clinical-stage program, expanding the Company's ophthalmology portfolio beyond retinal vascular disease into ocular surface disease HT006.2.2 is designed to offe…
Read attachment ↗nbp-ex99_1.htm · 6-K · 2026-09-08
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director • Martin Dewhurst appointed as independent director and member of the Audit and Compensation Committees • Veteran healthcare executive brings more than 30 years of leadership, governance, and strategic advisory experience ROCKVILLE, MD, September 8, 2026 (GLOBE NEWSWIRE) - NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innova…
Read attachment ↗nbp-ex99_1.htm · 6-K · 2026-08-20
Exhibit 99.1 NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution • Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders • Appointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to strengthen strategic oversight, governance, and capital allocation across the Company • Advancing givastomig toward initiating a registrational Phase 3 stud…
Read attachment ↗nbp-ex99_2.htm · 6-K · 2026-08-20
Exhibit 99.2 NovaBridge Biosciences Condensed Consolidated Balance Sheets As of June 30, 2026 and December 31, 2025 (Unaudited) (All amounts in thousands, except for share data, unless otherwise noted) As of …
Read attachment ↗nbp-ex99_1.htm · 6-K · 2026-08-20
Company Presentation NASDAQ: NBP August 2026 Disclaimer This presentation has been prepared by NovaBridge Biosciences (the “Company”) solely for informational purposes. Certain of the information included herein was obtained from various sources, including certain third parties, and has not been independently verified by the Company. By viewing or accessing the information contained in this presentation, you hereby acknowledge and agree that no representations, warranties, or undertakings, expr…
Read attachment ↗nbp-ex99_1.htm · 6-K · 2026-07-24
Exhibit 99.1 NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026 ROCKVILLE, MD, July 24, 2026 (GLOBE NEWSWIRE) - NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced that it will hold its annual general meeting of shareholders (the “AGM”) at NovaBridge Biosciences Shanghai office, 38F, AIA Tower, No. 866 Dongchangzhi Road, Shangh…
Read attachment ↗